• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Fatal graft-versus-host disease following HLA-mismatched donor lymphocyte infusion.

作者信息

Amrolia P J, Rao K, Slater O, Ramsay A, Veys P A, Webb D K

机构信息

Department of Bone Marrow Transplantation, Great Ormond Street Hospital for Sick Children, London, UK.

出版信息

Bone Marrow Transplant. 2001 Sep;28(6):623-5. doi: 10.1038/sj.bmt.1703195.

DOI:10.1038/sj.bmt.1703195
PMID:11607779
Abstract

We report the case of a 10-year-old boy with molecular relapse of CML following unrelated donor BMT who developed fatal grade 4 acute GVHD of the gut and liver following one antigen-mismatched donor lymphocyte infusion. Previous experience of donor lymphocyte infusion in the HLA-mismatched setting is reviewed and the role of adoptive immunotherapy in this situation is discussed.

摘要

相似文献

1
Fatal graft-versus-host disease following HLA-mismatched donor lymphocyte infusion.
Bone Marrow Transplant. 2001 Sep;28(6):623-5. doi: 10.1038/sj.bmt.1703195.
2
Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.供体白细胞输注用于日本异基因骨髓移植后复发白血病患者：急性移植物抗宿主病发生率较低且预后改善。
Bone Marrow Transplant. 2000 Oct;26(7):769-74. doi: 10.1038/sj.bmt.1702596.
3
Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors.
Bone Marrow Transplant. 1998 May;21(10):1055-61. doi: 10.1038/sj.bmt.1701224.
4
Adoptive cell-mediated immunotherapy with interleukin-2 (IL-2) for relapsing lymphoblastic crisis following mismatched unrelated bone marrow transplantation in a chronic myelogenous leukemia patient.
Bone Marrow Transplant. 1998 Jan;21(1):93-6. doi: 10.1038/sj.bmt.1701040.
5
Unexpected late graft failure 9 months after HLA-identical bone marrow transplant (BMT) for chronic myeloid leukemia (CML): treatment with a second BMT.
Haematologica. 1998 Mar;83(3):285-7.
6
Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.异基因反应性以及抗受体特异性产生白细胞介素2的辅助性T淋巴细胞前体细胞频率对骨髓移植后异基因反应性的预测价值。
Dan Med Bull. 2002 May;49(2):89-108.
7
Allogeneic bone marrow and peripheral stem cell transplantation from a haplo-identical mother and CD34 positive selection for CML.
Bone Marrow Transplant. 1996 Aug;18(2):449-52.
8
[Successful donor lymphocyte infusion for Epstein-Barr virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation from an HLA 1-locus-mismatched sibling donor in a patient with acute lymphocytic leukemia].
Rinsho Ketsueki. 2001 Nov;42(11):1105-10.
9
[Unrelated donor allogenetic marrow transplantation in treatment of acute and chronic leukemia].
Zhonghua Yi Xue Za Zhi. 2001 Mar 10;81(5):263-7.
10
Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.α干扰素联合极低剂量供体淋巴细胞输注治疗慢性髓性白血病血液学或细胞遗传学复发可诱导快速且持久的完全缓解，并与可接受的移植物抗宿主病相关。
Biol Blood Marrow Transplant. 2004 Mar;10(3):204-12. doi: 10.1016/j.bbmt.2003.11.003.

引用本文的文献

1
Recent Developments in Cellular Immunotherapy for HSCT-Associated Complications.造血干细胞移植相关并发症的细胞免疫治疗新进展
Front Immunol. 2016 Nov 14;7:500. doi: 10.3389/fimmu.2016.00500. eCollection 2016.
2
T-Cell Therapy: Options for Infectious Diseases.T细胞疗法：传染病的治疗选择
Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S217-24. doi: 10.1093/cid/civ615.